Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in High-Risk CLL
NCT01271283Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Dec 2010
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in chronic lymphocytic leukemia (CLL), sponsored by National Cancer Institute. Planned start Dec 2010; status: withdrawn.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01271283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01271283.